Salmi Abdul Razak, Farida Islahudin, Ahmad Fuad Shamsuddin, Nor Shuhaila Shahril
Salmi Abdul Razak1, Farida Islahudin2*, Ahmad Fuad Shamsuddin2, Nor Shuhaila Shahril1
1Putrajaya Hospital, Federal Government Administrative Centre, Precint 7, 62250 Putrajaya, Malaysia
2Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia
Volume - 6,
Issue - 5,
Year - 2013
Leflunomide is an effective disease-modifying anti rheumatic drug with reported adverse drug reactions. This retrospective study is aimed to quantify the incidence of adverse drug reactions and predict risk factors of leflunomide-induced liver injury in the treatment regimen of rheumatoid arthritis patients. Rheumatoid arthritis patients on leflunomide treatment were identified from a local tertiary hospital. Data was retrieved for 73 patients. A total number of 35 patients were found to have elevated liver enzyme levels during treatment with leflunomide. The mean onset of liver enzyme abnormalities occurred after 6.44 ± 8.11 months from the initiation of leflunomide in rheumatoid arthritis patients’ treatment regimen. Termination of disease-modifying anti rheumatic drug was found highest 15.1% (n=11) due to events of liver injury, followed by 12.3% (n=9) due to other adverse drug reactions. It has been shown that the type of rheumatoid factor (p=0.005) and dyslipidemia (p=0.029) are predictors to the incidence of liver injury based on liver enzyme abnormalities.
Cite this article:
Salmi Abdul Razak, Farida Islahudin, Ahmad Fuad Shamsuddin, Nor Shuhaila Shahril. A study on Leflunomide-induced liver injury in Rheumatoid Arthritis Patients. Research J. Pharm. and Tech. 6(5): May 2013; Page 556-561.